Target intelligence / Profile preview

Mitochondrial glutathione transporter SLC25A40 (SLC25A40)

Target
SLC25A40
Molecular classification
Transporter, Solute carrier family protein, Mitochondrial carrier protein
01

Overview

SLC25A40 is a mitochondrial inner membrane transporter belonging to the SLC25 family, which is the largest family of mitochondrial metabolite transporters in humans. SLC25A40 is highly homologous to SLC25A39, and together, they perform a redundant and essential role in the transport of glutathione into mitochondria. Glutathione (GSH) is synthesized in the cytosol and imported into mitochondria where it is crucial for mitigating oxidative stress, maintaining redox balance, and supporting the biogenesis of iron–sulfur clusters required for mitochondrial function. SLC25A40 and SLC25A39 have been shown to be evolutionarily conserved, with loss-of-function in both resulting in severe mitochondrial dysfunction and impaired cell viability, particularly impacting erythropoiesis and potentially other processes reliant on mitochondrial integrity. While SLC25A39 is more strongly implicated in cancer metabolism, SLC25A40’s biological significance is evidenced in genetic screens and knockout models, but its therapeutic targeting and disease association remain less characterized. No small-molecule inhibitors, interacting drugs, or clinically validated biomarkers are reported for SLC25A40.

Other names
SLC25A40mitochondrial carrier family protein (MCFP)solute carrier family 25 member 40probable mitochondrial glutathione transporter SLC25A40
02

Biological functions

Glutathione import into mitochondriaOxidative metabolism regulationMaintenance of mitochondrial redox homeostasisSupport of iron–sulfur cluster biogenesis
03

Disease associations

Cancer (altered metabolism in cancer, though its role as a direct cancer target is less clear than SLC25A39)Anemia (critical for erythropoiesis in animal models)Potential contributor to neurodegenerative and metabolic disorders via oxidative stress regulation (based on glutathione biology; direct evidence for SLC25A40 is limited)
04

Safety considerations

No specific therapeutic safety concerns described, as SLC25A40 is not yet a clinical drug target; knockout models show impaired proliferation and mitochondrial dysfunction

Beyond the preview

Go deeper on Mitochondrial glutathione transporter SLC25A40 (SLC25A40).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial glutathione transporter SLC25A40 (SLC25A40).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call